Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria

Kidney International

Volumn 75, Issue 11, 2009, Pages 1184-1193

  Pinheiro, Sérgio V B ^a   Ferreira, Anderson J ^a   Kitten, Gregory T ^a   Da Silveira, Kátia D ^a   Da Silva, Deivid A ^a   Santos, Sérgio H S ^a   Gava, Elisandra ^a   Castro, Carlos H ^a   Magalhes, Jnio A ^a   Da Mota, Renata K ^a   Botelho Santos, Giancarla A ^a   Bader, Michael ^b   Alenina, Natalia ^b   Santos, Robson A S ^a   Simoes E Silva, Ana Cristina ^a,c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c NONE   (Brazil)

Author keywords

Angiotensin II; Angiotensin (17); AT1 receptor; Receptor Mas; Renal fibrosis; Transforming growth factor

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; COLLAGEN TYPE 3; COLLAGEN TYPE 4; FIBRONECTIN; MESSENGER RNA; PROTEIN MAS; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROGENESIS; GENE DELETION; GLOMERULUS FILTRATION; INULIN CLEARANCE; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; KNOCKOUT MOUSE; MALE; MESANGIUM; MICROALBUMINURIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SODIUM EXCRETION; URINE VOLUME;

ALBUMINURIA; ANIMALS; COLLAGEN; FIBRONECTINS; FIBROSIS; GENE DELETION; GLOMERULAR FILTRATION RATE; KIDNEY GLOMERULUS; MICE; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; UP-REGULATION;

EID: 67349127050     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.61     Document Type: Article

References (63)

1. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin angiotensin aldosterone system. Nat Rev Drug Discov 2002; 1: 621-636.
2. Ferrario CM, Chappell MC. Novel angiotensin peptides. Cell Mol Life Sci 2004; 61: 2720-2727.
3. Simões e Silva AC, Pinheiro SVB, Pereira RM et al. The therapeutic potential of Angiotensin-(1-7) as a novel renin angiotensin system mediator. Mini-Rev Med Chem 2006; 6: 603-609.
4. Santos RAS, Ferreira AJ, Simoes e Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 2008; 93: 519-527.
5. Albiston AL, McDowall SG, Matsacos D et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001; 276: 48623-48626.
6. Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin- converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin-(1-9). Circ Res 2000; 87: 1-9.
7. Tipnis SR, Hooper NM, Hyde R et al. A human homolog of Angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-33243.
8. Santos RAS, Simões e Silva AC, Maric C et al. Angiotensin-(1-7) is an endogenous ligand for the G-protein coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263.
9. Simões e Silva AC, Diniz JS, Regueira-Filho A et al. The Renin Angiotensin System in childhood hypertension: Selective increase of Angiotensin-(1-7) in essential hypertension. J Pediatr 2004; 145: 93-98.
10. Simões e Silva AC, Diniz JS, Pereira RM et al. Circulating Renin Angiotensin System in childhood chronic renal failure: Marked increase of Angiotensin-(1-7) in end-stage renal disease. Pediatr Res 2006; 60: 734-739.
11. Maia LG, Ramos MC, Fernandes L et al. Angiotensin-(1-7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J Cardiovasc Pharmacol 2004; 43: 685-691.
12. Höcht C, Gironacci MM, Mayer MA et al. Involvement of angiotensin-(1-7) in the hypothalamic hypotensive effect of captopril in sinoaortic denervated rats. Regul Pept 2008; 146: 58-66.
13. Ishiyama Y, Gallagher PE, Averill DB et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43: 970-976.
14. Kostenis E, Milligan G, Christopoulos A et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005; 111: 1806-1813.
15. Canals M, Jenkins L, Kellett E et al. Up-regulation of the angiotensin II type 1 receptor by the Mas proto-oncogene is due to constitutive activation of Gq/G11 by Mas. J Biol Chem 2006; 281: 16757-16767.
16. Santos RAS, Castro CH, Gava E et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor Mas knockout mice. Hypertension 2006; 47: 996-1002.
17. Xu P, Costa-Goncalves AC, Todiras M et al. Endothelial dysfunction and elevated blood pressure in Mas gene-deleted mice. Hypertension 2008; 51: 574-580.
18. Costa Gonçalves AC, Leite R, Fraga-Silva RA et al. Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function. Am J Physiol Heart Circ Physiol 2007; 293: H2588-H2596.
19. Fraga-Silva RA, Pinheiro SV, Gonçalves AC et al. The antithrombotic effect of angiotensin-(1-7) involves Mas-mediated NO release from platelets. Mol Med 2008; 14: 28-35.
20. Santos SH, Fernandes LR, Mario EG et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008; 57: 340-347.
21. Hansen PB, Yang T, Huang Y et al. Plasma renin in mice with one or two renin genes. Acta Physiol Scand 2004; 181: 431-437.
22. Navar LG, Nishiyama A. Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens 2004; 13: 107-115.
23. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004; 116: 263-272.
24. Arendshorst WJ, Brannstrom K, Ruan X. Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 1999; (Suppl 11): S149-S161.
25. Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 1999; (Suppl 12): S258-S265.
26. Ren Y, Garvin JL, Carretero AO. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 2002; 39: 799-802.
27. Sampaio WO, Nascimento AA, Santos RAS. Systemic and regional hemodynamics effects of angiotensin-(1-7) in rats. Am J Physiol 2003; 284: H1985-H1994.
28. 3H] norepinephrine from rat atria. Hypertension 1994; 24: 457-460.
29. Frokiaer J, Nielsen S, Knepper MA. Molecular physiology of renal aquaporins and sodium transporters: Exciting approaches to understand regulation of renal water handling. J Am Soc Nephrol 2005; 16: 2827-2829.
30. Oudit GY, Herzenberg AM, Kassiri Z et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006; 168: 1808-1820.
31. Pereira RM, Santos RAS, Teixeira MM et al. The Renin Angiotensin System in a rat model of hepatic fibrosis: Evidence for a protective role of Angiotensin-(1-7). J Hepatol 2007; 46: 674-681.
32. Kuncio GS, Neilson EG, Haverty TP. Mechanisms of tubulointerstitial fibrosis. Kidney Int 1992; 39: 550-556.
33. Harris RC, Neilson EG. Toward a unified theory of renal progression. Annu Rev Med 2006; 57: 365-380.
34. Fakhouri F, Placier S, Ardaillou R et al. Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-β. J Am Soc Nephrol 2001; 12: 2701-2710.
35. Remuzzi A, Gagliardini E, Donadoni C et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002; 62: 885-894.
36. Boffa JJ, Lu Y, Placier S et al. Regression of renal vascular and glomerular fibrosis: Role of Angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14: 1132-1144.
37. Chen S, Lee JS, Iglesias-de la Cruz MCI et al. Angiotensin II stimulates a3(IV) collagen production in mouse podocytes via TGF-β and VEGF signaling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 2005; 20: 1320-1328.
38. Ma LJ, Fogo A. Modulation of glomerulosclerosis. Semin Immunopathol 2007; 29: 385-395.
39. Border WA, Okuda S, Languino LR et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990; 346: 371-374.
40. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 2006; 70: 1914-1919.
41. August P, Suthanthiran M. Transforming growth factor beta and progression of renal disease. Kidney Int 2003; (Suppl 87): S99-S104.
42. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-217.
43. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol 2005; 289: 1560-1566.
44. Machado RD, Ferreira MA, Belo AV et al. Vasodilator effect of angiotensin-(1-7) in mature and sponge-induced neovasculature. Regul Pept 2002; 107: 105-113.
45. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003; 42: 574-579.
46. Gallagher PE, Tallant EA. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 2004; 25: 2045-2052.
47. Iwata M, Cowling RT, Gurantz D et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effcts. Am J Physiol 2005; 289: 2356-2363.
48. Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 2006; 69: 2212-2218.
49. Wysocki J, Ye M, Soler MJ et al. ACE and ACE2 activity in diabetic mice. Diabetes 2006; 55: 2132-2139.
50. Ye M, Wysocki J, William J et al. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006; 17: 3067-3075.
51. Wong DW, Oudit GY, Reich H et al. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 2007; 171: 438-451.
52. Soler MJ, Wysocki J, Ye M et al. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007; 72: 614-623.
53. Anderson S, Meyer TW, Rennke HG et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619.
54. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803-1817.
55. Azizi M, Ménard J. Combined blockade of the Renin Angiotensin System with Angiotensin-converting enzyme inhibitors and Angiotensin II type 1 receptor antagonists. Circulation 2004; 109: 2492-2499.
56. Codreanu I, Perico N, Remuzzi G. Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection? J Am Soc Nephrol 2005; (Suppl 1): S34-S38.
57. Qi Z, Whitt I, Mehta A et al. Serial determination of glomerular filtration rate in conscious mice using FITC-Inulin clearance. Am J Physiol Renal Physiol 2004; 286: 590-596.
58. Davidson WD, Sackner MA. Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 1963; 62: 351-356.
59. Gervais M, Demolis SP, Domerg V et al. Systemic and regional hemodynamics assessment in rats with fluorescent microspheres. J Cardiovasc Pharmacol 1999; 33: 425-432.
60. Glenny RW, Bernard S, Brinkley M. Validation of fluorescent-labeled microspheres for measurement of regional organ perfusion. J Appl Physiol 1993; 74: 2585-2597.
61. Van Oosterhout MFM, Willigers MM, Renaman RS et al. Fluorescent microspheres to measure organ perfusion: validation of a simplified sample processing technique. Am J Physiol Heart Circ Physiol 1995; 269: H725-H733.
62. de Oliveira GV, Sanford AP, Murphy KD et al. Growth hormone effects on hypertrophic scar formation: a randomized controlled trial of 62 burned children. Wound Repair Regen 2004; 12: 404-411.
63. Souza BR, Motta BS, Rosa DVF et al. DARPP-32 and NCS-1 expression is not altered in brains of rats treated with typical or atypical antipsychotics. Neurochem Res 2008; 33: 533-538.